Lin Chengbin, Xi Yong, Yu Hongyan, Chen Xiaohan, Shen Weiyu
Department of Thoracic Surgery, the Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.
J Thorac Dis. 2022 Feb;14(2):536-545. doi: 10.21037/jtd-22-118.
The Tumor Node Metastasis (TNM) stage cannot accurately predict the prognosis of patients in pulmonary squamous cell carcinoma (SQCC). The aim of the present study was to evaluate the prognostic value of immunohistochemical (IHC)-based classifiers in patients with pulmonary SQCC who underwent complete surgery resection.
From January 2010 to December 2014, a total of 556 patients with SQCC who underwent complete radical resection were included. The patients were grouped into a discovery group (n=334) and a validation group (n=222). Using the least absolute shrinkage and selection operator (LASSO) regression model, we extracted IHCs that were associated with progression-free survival (PFS) and then built classifiers. Clinicopathological variables and the IHC-based classifiers were analyzed using univariable and multivariable logistic regression analyses. A nomogram to predict PFS was constructed and validated using bootstrap resampling.
Following the LASSO regression model, 4 IHC markers associated with PFS were identified. We used the IHC-based classifiers to stratify patients in both groups into high- and low-risk groups. PFS was better in the low-risk group than in the high-risk group in both the discovery and validation groups. Multivariate analysis demonstrated that the IHC-based classifiers were independently prognostic in predicting the PFS of patients with SQCC. The performance of the nomogram was evaluated and proven to be clinically useful.
By combining IHC-based classification and clinicopathology, we were able to have better insight into the prognostic assessment of patients with SQCC after surgery, which can inform postoperative patient management.
肿瘤淋巴结转移(TNM)分期无法准确预测肺鳞状细胞癌(SQCC)患者的预后。本研究旨在评估基于免疫组织化学(IHC)的分类器对接受完整手术切除的肺SQCC患者的预后价值。
纳入2010年1月至2014年12月期间共556例行完整根治性切除的SQCC患者。将患者分为发现组(n = 334)和验证组(n = 222)。使用最小绝对收缩和选择算子(LASSO)回归模型,提取与无进展生存期(PFS)相关的免疫组化指标,然后构建分类器。采用单变量和多变量逻辑回归分析对临床病理变量和基于免疫组化的分类器进行分析。构建预测PFS的列线图,并使用自助重采样进行验证。
根据LASSO回归模型,确定了4个与PFS相关的免疫组化标志物。我们使用基于免疫组化的分类器将两组患者分为高风险组和低风险组。在发现组和验证组中,低风险组的PFS均优于高风险组。多变量分析表明,基于免疫组化的分类器在预测SQCC患者的PFS方面具有独立的预后价值。对列线图的性能进行了评估,并证明其具有临床实用性。
通过结合基于免疫组化的分类和临床病理学,我们能够更好地了解SQCC患者术后的预后评估,这可为术后患者管理提供参考。